TMO · Archiwum opublikowanych analiz

2026maj

TMO May 2026 · Hold

Thermo Fisher Scientific is the dominant, scale-advantaged player in life sciences tools and diagnostics. Its comprehensive portfolio, deep customer relationships, and proven M&A integration engine drive consistent cash flow generation and mid-single-digit organic growth over the long term. However, elevated debt levels and the sheer scale of operations are expected to naturally decelerate its historical M&A-driven compounding trajectory.Historical archived edition · analyzed 2026-05-09

Trzymaj

474,46 USD

TMO · Archive

Historia rekomendacji